Gut microbiome may impact HIV vaccine immune responses

 MADRID, SPAIN – OCTOBER 23, 2018 – Preliminary evidence presented at the HIV Research for Prevention (R4P) Conference in Madrid, Spain suggests that the composition of the human gut microbiome may inform how well an experimental HIV vaccine can elicit an immune response. Vaccines reduce the risk of an infection by helping the human immune system to fight disease without exposing it to disease symptoms.

 In a late breaker abstract presentation titled: Human gut microbiota are associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination, James Kublin M.D. of the HIV Vaccine Trials Network (HVTN) explained that the human microbiome and immune system shape each other through lifelong interactions. He and his team used 16S ribosomal RNA sequencing of stool samples to understand the role of the human gut microbiome in modulating the immune response to two experimental HIV vaccines.

 Read more:

Aziel Gangerdine

Director of Communications

HIV Vaccine Trials Network (HVTN)

Office: +1 206.667.7875

Cell: +1 206.384.0945

agangerd@fredhutch.org

http://www.fredhutch.org/content/dam/public/email-signatures/3/fred_hutch_logo.png
HIV Vaccine Trials Network (HVTN)

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N., Mail Stop E3-300
Seattle, WA 98109
fredhutch.org